Semaglutide, the active ingredient in Ozempic and Wegovy, is one of a class of glucagon-like peptide-1 receptor agonists—GLP-1s—that activate receptors in areas of the brain that regulate alcohol cravings. A 2025 Phase II trial gave semaglutide to adults with alcohol use disorder. People on semaglutide drank less often, drank less heavily, and reported fewer cravings (Hendershot et al., 2025). Separately, a study that followed over 227,000 patients found those taking it ended up in the hospital for drinking-related reasons 36% less often (Lähteenvuo et al., 2025). The FDA hasn't approved it for alcohol use disorder yet, but people are asking about it—and the questions are grounded in something real. Inside residential treatment, the medication can be assessed, monitored, and combined with evidence-based therapies in real time.
My doctor mentioned semaglutide might help with my drinking, and I haven't been able to stop reading about it since
There's a specific feeling that arrives when you read about something late at night and think: what if this is actually real.Your doctor said the word semaglutide, you nodded politely in the office, and then you came home and started reading. Hours later, you're still reading. The hope you're holding right now is tracking real science.
GLP-1, short for glucagon-like peptide-1, is a hormone your gut already makes after meals. It manages blood sugar and tells your body it's full. Scientists noticed something else along the way—GLP-1 receptors also sit inside parts of the brain that handle desire, including the desire to drink (Bruns et al., 2024).
Those parts of the brain have clinical names like the ventral tegmental area and the nucleus accumbens. In everyday language, these are the structures that light up when something promises reward. Early studies suggest that GLP-1 receptor activation can significantly reduce voluntary alcohol intake. Give semaglutide to an animal and it drinks less. Consistently, across different doses, male and female alike (Aranäs et al., 2023). The effects of alcohol on the brain's reward system were quieted at a level deeper than willpower.
So when your doctor mentioned semaglutide, they were pointing at something real.
What the 2026 clinical trials actually found—and why researchers are calling this a turning point
The lab quietly catching up to what some people were already noticing in their own lives is one of the more affecting moments in recent addiction research. In a double-blind, placebo-controlled trial running into 2025, forty-eight adults with alcohol use disorder were randomly assigned to receive either once-weekly semaglutide or a placebo over nine weeks. The people who got semaglutide drank less, and the days they did drink were less heavy (Hendershot et al., 2025).
A heavy drinking day, in research terms, usually means four drinks or more for a woman and five or more for a man. The number of heavy drinking days is one of the primary measures researchers use to understand how much someone's alcohol consumption has actually changed—not just what they report feeling. When that number drops, so does the morning after. And fewer of those mornings stack up in ways that quietly change every decision that follows.
The other 2025 finding was larger in scale, and its public health implications are significant. A registry study tracking over 227,000 patients in Denmark and Sweden found that people prescribed semaglutide had a 36% lower risk of alcohol-related hospitalizations than those who weren't taking it. Liraglutide, an older GLP-1 drug, came in at 28%. Naltrexone, the longest-standing medication used to treat alcohol use disorder, showed a 14% reduction in the same data (Lähteenvuo et al., 2025). Researchers publishing in JAMA Psychiatry noted that the treatment gap between how many people need help and how many receive effective care has been a persistent public health concern—and GLP-1s are being studied as one way to begin closing it. The lab and the real world are pointing the same direction.
I was on Ozempic for something else and barely touched alcohol for three months—is that a coincidence?
You weren't imagining it. Other people noticed the same thing on Ozempic or Wegovy, and the science is starting to explain why. The medication was prescribed for your weight, your blood sugar, your insulin resistance—and then a few weeks in you noticed that your glass of wine sat untouched on the counter. You forgot to think about happy hour. The Friday craving didn't show up.
The registry data mentioned earlier looked at over 227,000 patients, many of whom were taking GLP-1 drugs for treating diabetes and obesity, not for alcohol problems specifically. The drop in alcohol-related hospitalizations showed up across that broader population anyway (Lähteenvuo et al., 2025). The medication was doing one job on paper and a quieter second job in the background.
Animal studies had pointed at this earlier. When researchers gave semaglutide to rats who hadn't been selected for alcohol issues, the rats simply drank less. Male animals, female animals, different doses—same result (Aranäs et al., 2023). The brain's reward circuitry doesn't read the label on a prescription. It just responds. That's why researchers are now looking at the potential for GLP-1s to treat multiple forms of addiction—alcohol and substance use disorders among them—as a tool for dialing down compulsive reward-seeking at its source.
You noticed something real. The door you happened to walk through is a real door.
If you have questions about how GLP-1 fits into a full treatment plan, we're here to walk through it with you. Ask Us Anything
If a medication can quiet the craving, does that mean I don't actually need to go to rehab?
This is the question underneath all the others. You may not have typed it into the search bar, but you've been carrying it for hours. Could a weekly injection mean the thing you've been dreading most—the residential program, the time off work, the people who would know—doesn't have to happen? That question deserves a full answer before anything else.
The research speaks to this directly. Semaglutide does something targeted and real in the reward system. In the Phase II trial, therapy and daily medical support were part of the plan from day one. Semaglutide was never tested alone (Hendershot et al., 2025).
A separate study compared semaglutide to drugs that raise the body's own GLP-1 without directly activating its receptors. The receptor-activating drugs worked on alcohol intake. The indirect ones did not (Farokhnia et al., 2025). The mechanism is real and specific, which is why dosing, response, and integration with other care need clinical oversight.
GLP-1 medication quiets the craving signal in the brain. That's one part of what alcohol use disorder does inside a person. Trauma, the behavioral patterns built around drinking, relationship damage, and the depression or anxiety that often sit underneath are other parts. No single medication addresses all of them, and none should be expected to. Effective treatment for alcohol use disorder has always involved a combination of treatment options—medication, therapy, and structured support working together. Addiction treatment that integrates GLP-1 alongside that broader plan is something a medically supervised residential setting can assess for you specifically, calibrate in real time, and monitor around the clock during the period when the body is adjusting to something new.
What happens when the depression or the anxiety is wrapped up in the drinking too—does GLP-1 change anything for dual diagnosis?
If you've been told the drinking is just self-medication for something else, you've probably also been told the opposite—that the anxiety or the depression is just the drinking talking. Neither framing tells the full story. The clinical reality, when both conditions are active at the same time, is that they need to be addressed together. Dual diagnosis is the term for that: a substance use disorder and a mental health condition running concurrently, each one affecting the other.
A 2025 analysis that pooled data from twenty-seven randomized controlled trials and more than 59,000 patients looked specifically at whether GLP-1 medications raise the risk of psychiatric problems like suicidal thoughts or worsening mood. The analysis found no significant increase (Ebrahimi et al., 2025). For someone who's been turned away or shrugged off because of co-occurring mental health concerns, that finding removes one real fear. It matters especially for people living with alcohol use disorder and comorbid anxiety or depression, where the overlap between alcohol and substance use disorders and mental health conditions is often the hardest part to untangle.
A separate 2025 review noted something still being studied. The same brain pathways involved in alcohol cravings—including the reward system and the stress-response system—are also involved in how depression and anxiety move through the body. Researchers have also observed similar reward-pathway effects in drug addiction and tobacco use disorder, suggesting that GLP-1s may eventually have relevance across a wider range of compulsive use patterns. For people dealing with obesity and alcohol use disorder together, or use disorder and comorbid obesity as part of a more complex clinical picture, the overlapping mechanisms are part of why supervised integration matters (Srinivasan et al., 2025).
Our program is built on the premise that co-occurring conditions require integrated care from day one. Your psychiatric needs, your medication response, and the work of recovery all happen on the same plan, watched by the same team.
Co-occurring conditions deserve co-occurring care—and that's exactly what we're built for.
Talk to the Wish Team
Who is actually a good candidate for semaglutide in alcohol recovery—and who should think carefully before moving forward?
Personalization matters here more than for most medications. GLP-1 works through a specific pathway in the brain, and two people can take the same dose and have very different outcomes. A regular doctor's office prescribing it off-label doesn't usually see you every day—and daily visibility is what catching that difference actually requires (Farokhnia et al., 2025).
Better candidates tend to be patients with alcohol use disorder as their primary diagnosis, with or without comorbid obesity or type 2 diabetes where GLP-1 is already indicated. People who haven't responded well to naltrexone or acamprosate—the established AUD medications and longest-standing medications for alcohol use disorder—are also part of the conversation. Medications for addiction treatment work best when they're matched to the individual, and prescribing GLP-1s off-label for someone whose primary issue is opioid or stimulant use is usually a separate clinical picture with less supporting evidence.
There are reasons for caution too. Active suicidal ideation, pending more data in this population. A personal or family history of medullary thyroid cancer or a condition called MEN2 is a hard contraindication, as it is for all GLP-1 medications. Active pancreatitis and pregnancy planning each call for a different conversation entirely. Earlier preclinical research also found that not every animal model showed consistent alcohol reduction on GLP-1—a reminder that human response will likely vary widely as well (Bornebusch et al., 2019).
If your liver has taken a hit from years of heavy drinking—which is common, and not a moral failure—a medically supervised assessment is the only way to know what dosing should look like for you specifically. No two people in our program receive the same protocol, because no two people arrive with the same body or the same history.
What personalized GLP-1 integration actually looks like inside a medically supervised residential program
Most articles about this medication stop before they get to this part. Here's the shape of it in our program.
Before any conversation about GLP-1, we do a full medical and psychiatric evaluation. Liver function, metabolic markers, current medications, sleep, and a careful conversation about what's been happening for you emotionally. Everything that follows is built on what we learn there (Hendershot et al., 2025).
Titration—the slow ramp-up that semaglutide requires to minimize stomach side effects—happens inside a setting where someone sees you every day. Outpatient titration without daily monitoring is a different experience entirely. Inside residential care, your medical team notices early if something needs adjusting.
When the craving signal gets quieter, the rest of the work becomes possible in a new way. CBT, or cognitive behavioral therapy, helps you recognize and rework the thinking patterns that lead toward drinking. EMDR, which stands for Eye Movement Desensitization and Reprocessing, helps the body process trauma memories so they stop driving present behavior. With less neurological noise from craving, more mental bandwidth is available for both. The medication and the therapy work as one coordinated system, not two parallel tracks that never meet.
The only published human trial of a GLP-1 medication inside a residential substance use program ran in 2024. The trial protocol required the inpatient structure—without it, the daily monitoring and dose calibration that made the results meaningful wouldn't have been possible (Freet et al., 2024). Much of the foundational research on treating alcohol use disorder with GLP-1s has been supported through funding from the National Institutes of Health, including the National Institute on Alcohol Abuse and Alcoholism—an arm of the NIH that also supports the Alcohol Clinical Trials Initiative—and the National Institute on Drug Abuse, reflecting how seriously the field is taking this question. Earlier laboratory studies using alcohol self-administration models in animals, along with work coming out of institutions like the Institute for Addiction Science, helped establish the neurological rationale that shaped human trial design.
With twelve clients at a time here in LA, our team can know each person well enough to integrate what semaglutide is doing with everything else in the plan—something that prescribing GLP-1s off-label in a standard outpatient setting simply can't replicate. Three weeks in, when the craving has gone quiet and someone calls you by name in the dining room, that's the texture of what we're describing.
The conversation is confidential, there's no obligation, and you don't need to have anything figured out to reach out. Contact Wish
What this research still can't tell us—and why that honest gap matters before you make any decision
If you've read this far, you deserve an honest answer about what we don't know yet about GLP-1 therapies for alcohol use disorder.
We don't know how long the craving reduction lasts after semaglutide is stopped. Treatment duration in the trials has run weeks to months, not years. Whether the efficacy holds over time—or whether it requires continued medication—is still an open clinical question (Srinivasan et al., 2025). Researchers in population and public health sciences are working to understand how to measure long-term outcomes in this population in a way that goes beyond what a single placebo-controlled trial can show.
The optimal dose for alcohol use disorder hasn't been settled either. Each randomized clinical trial has used doses developed for metabolic conditions. Whether those doses are right for someone whose primary issue is drinking is still being worked out. The World Health Organization's risk drinking levels and definitions of harmful consumption haven't yet been fully integrated into trial design for this indication.
How different people respond to the same medication is also a real factor. The Phase II trial had forty-eight participants. The registry studies are larger but include people taking GLP-1 for other reasons. Earlier preclinical work showed that not every animal model responded to GLP-1 on alcohol-seeking behavior the same way (Bornebusch et al., 2019). Some people may respond strongly. Others may not respond at all. Researchers have also noted that while GLP-1s have shown the potential to reduce nicotine self-administration and may help reduce compulsive use across multiple substances, the efficacy in humans for anything beyond alcohol and weight-related outcomes is still being studied. That potential use across multiple domains is promising—but it's early, and honesty about that matters.
And semaglutide still has no FDA approval for AUD as of 2026. Off-label prescribing happens, and it isn't malpractice—but it means the insurance infrastructure, the post-market monitoring, and the standardized clinical protocols that surround approved uses are still being built.
You don't have to figure this out alone in a browser tab at midnight
Reaching for something that might help is the same intelligence that built the research you've been reading tonight. You don't have to have everything figured out to take the next step. Our team at Wish is here, the conversation is private, and there's no pressure in either direction. We'll be here when you're ready.
When you're ready to take the next step, we'll handle the details—including working through your coverage. Explore Your Insurance Options
Frequently Asked Questions
Is semaglutide FDA-approved for alcohol use disorder?
No. Semaglutide doesn't have FDA approval for alcohol addiction as of 2026. Doctors are using it off-label in supervised settings while the research continues. Formal approval may come in the years ahead.
How does GLP-1 affect alcohol cravings?
GLP-1 receptors are found in the parts of the brain that process reward and desire—including the structures activated by alcohol. When those receptors are activated by a medication like semaglutide, the craving signal can become quieter. The mechanism works at a neurological level, below the reach of willpower alone.
Can I take Ozempic or Wegovy to stop drinking on my own?
These are diabetes medications that have been shown to reduce alcohol cravings as an off-label effect. They require a prescription and medical oversight. Taking it without medical oversight carries real risks—especially if your liver has been stressed by drinking, if you're on other medications, or if there's something else going on mentally. A supervised program is the right place to sort that out.
Does GLP-1 treatment replace therapy or rehab?
No. GLP-1 medications address one part of what alcohol use disorder does in the brain. Therapy, dual-diagnosis care, trauma processing, and the behavioral and relational work of recovery address the rest. The research showing the most meaningful results combined semaglutide with structured therapeutic support.
Who is not a good candidate for GLP-1 in alcohol recovery?
People with a personal or family history of medullary thyroid cancer or a condition called MEN2 should not use GLP-1 medications. Active pancreatitis, pregnancy planning, and active suicidal ideation each require a different clinical conversation. Individual response also varies—supervised assessment is the only way to know whether this approach is appropriate for a specific person.
References
Aranäs, C., Edvardsson, C. E., Shevchouk, O. T., et al. (2023). Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine, 93, 104642. https://doi.org/10.1016/j.ebiom.2023.104642
Bornebusch, A. B., Fink-Jensen, A., Wörtwein, G., et al. (2019). Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs. eNeuro, 6(2). https://doi.org/10.1523/ENEURO.0443-18.2019
Bruns, C. M., Kemnitz, J. W., & Rinaman, L. (2024). GLP-1 receptor agonists and alcohol use disorder: Neurobiological mechanisms and therapeutic implications. Pharmacological Research, 201, 107312. https://doi.org/10.1016/j.phrs.2024.107312
Ebrahimi, R., Kamrani, A., Sharifi, A., et al. (2025). Psychiatric safety of GLP-1 receptor agonists: Systematic review and meta-analysis of 27 randomized controlled trials. JAMA Psychiatry, 82(2). https://doi.org/10.1001/jamapsychiatry.2025.0091
Farokhnia, M., Vinson, E., McGinn, M. A., et al. (2025). Direct GLP-1 receptor activation is necessary for alcohol reduction: Evidence from DPP-4 inhibitor studies. Journal of Clinical Investigation, 135(4). https://doi.org/10.1172/jci188314
Freet, C. S., Figueiredo, M., Patel, J., et al. (2024). GLP-1 receptor agonist treatment in inpatient opioid use disorder: A pilot randomized controlled trial. Addiction Science & Clinical Practice, 19, 27. https://doi.org/10.1186/s13722-024-00481-7
Hendershot, C. S., Wardell, J. D., Gilmour, A., et al. (2025). Semaglutide and alcohol use disorder: A randomized controlled trial. JAMA Psychiatry, 82(3). https://doi.org/10.1001/jamapsychiatry.2024.4789
Lähteenvuo, M., Tiihonen, J., Taipale, H., et al. (2025). GLP-1 receptor agonists and risk of alcohol-related hospitalizations: A nationwide registry study. JAMA Psychiatry, 82(1). https://doi.org/10.1001/jamapsychiatry.2024.3599
Srinivasan, V., Nagarkatti, P., & Nagarkatti, M. (2025). GLP-1 therapeutics and their emerging role in alcohol use disorder. Journal of the Endocrine Society, 9(3). https://doi.org/10.1210/jendso/bvaf141
June 01, 2026
